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Background: Aged individuals respond poorly to vaccination and have a higher risk of contracting infections in
comparison to younger individuals; whether age impacts on the composition and function of B cell
subpopulations relevant for immune responses is still controversial. It is also not known whether increased age
during HIV-1 infection further synergizes with the virus to alter B cell subpopulations. In view of the increased
number of HIV-1 infected patients living to high age as a result of anti-retroviral treatment this is an important
issue to clarify.
Results: In this work we evaluated the distribution of B cell subpopulations in young and aged healthy
individuals and HIV-1 infected patients, treated and naïve to treatment. B cell populations were characterized for
the expression of inhibitory molecules (PD-1 and FcRL4) and activation markers (CD25 and CD69); the capacity of
B cells to respond to activation signals through up-regulation of IL-6 expression was also evaluated. Increased
frequencies of activated and tissue-like memory B cells occurring during HIV-1 infection are corrected by
prolonged ART therapy. Our findings also reveal that, in spite of prolonged treatment, resting memory B cells in
both young and aged HIV-1 infected patients are reduced in number, and all memory B cell subsets show a low
level of expression of the activation marker CD25.
Conclusions: The results of our study show that resting memory B cells in ART-treated young and aged HIV-1 infected
patients are reduced in number and memory B cell subsets exhibit low expression of the activation marker CD25.
Aging per se in the HIV-1 infected population does not worsen impairments initiated by HIV-1 in the memory B cell
populations of young individuals.
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The administration of highly active antiretroviral therapy
(ART) to HIV-1 infected patients has led to improved
health conditions and increased life expectancy in many
treated individuals. As an example, it has been reported
that in the United States by 2015, half of the ART
treated patients will reach age 50 or older [1]. This in-
crease in life expectancy and age does not always relate
to a life free of illness conditions: in fact non-AIDS* Correspondence: francesca.chiodi@ki.se
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unless otherwise stated.conditions, including cardiovascular diseases, osteopor-
osis, renal and liver diseases, neurocognitive impair-
ments and cancer, are all increasing in this group of
HIV-1 treated patients [1].
A tremendous variety of immune dysfunctions that
takes place during HIV-1 infection can be directly linked
to the replication of the virus in target cells but also to
bystander mechanisms of immunological damage trig-
gered by the virus. Microbial translocation through the
damaged epithelial barrier in the gut [2] fuels events
leading to inflammation and apoptosis of immune cells
in lymphoid compartments and circulation. The con-
tinuous immunological activation taking place duringd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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features which are signatures of aging in healthy individ-
uals. In this respect the term “exhaustion” is often used
to characterize poor responses to activation signals by
expanded T-cell populations during HIV-1 infection [3].
B cells can be divided into several distinct subpopula-
tions according to lineage and differentiation markers; the
characterization of B cell subpopulations in the blood of
HIV-1 infected patients has revealed that profound alter-
ations take place in the composition of the B cell pool
during HIV-1 infection [4,5]. Immature transitional B cells,
which derive from progenitor B cells residing in the bone
marrow (BM) characterized by the expression of the CD10
lineage marker and the absence of CD27 expression [6,7],
tissue-like memory B cells similar to tonsillar B cells in ex-
pression of the inhibitory receptor Fc-receptor-like-4
(FcRL4) [8] and B cells with plasmablast characteristics
and low CD21 expression classified as activated memory B
cells [9] are all increased in the blood of viremic HIV-1 in-
fected individuals.
In contrast, a reduced number of resting memory B
cells has been found in blood samples of HIV-1 infected
patients [10-12]. Memory B cell functions improve by
early initiation of ART in adults and children [13,14].
However, once the depletion of memory B cells is estab-
lished during chronic HIV-1 infection, the replenish-
ment of this memory B cell population may be difficult
to correct, even following a prolonged period of treat-
ment. Accordingly, the administration of ART during
chronic HIV-1 infection leads to normalization of all the
B cell subsets with the exception of resting memory B
cells [15]. That the proportion of resting memory B cells
remains low in spite of viremia control indicates that
several pathological mechanisms may impact on B cell
dysfunctions during HIV-1 infection, including T-cell
lymphopenia and hyperactivation [16].
This persistent feature of B cell immunopathology
may have relevant clinical consequences, as resting
memory B cells are responsible for serological memory
against vaccination antigens and pathogens encountered
during life. Accordingly, the reduction of memory B cells
during HIV-1 infection may lead to a weakened B cell
immunity to vaccines [17-20]. Interestingly, effective
humoral immunity is also compromised in healthy indi-
viduals during aging, with poor antibody response to
many vaccines and increased susceptibility to infections
which rely on antibody control [21]; this weakened im-
mune response in elderly people has been linked to im-
pairment of somatic hypermutation and class switch
recombination as reviewed in [22,23].
The effect of age on the distribution of B cell subpopula-
tions has not been evaluated in detail [24]; furthermore, it
is unknown whether increased age during HIV-1 infection
further synergizes with the virus to affect the distributionof B cell subpopulations. In the present work we evaluated
the impact of age on the distribution of B cell subpopula-
tions in healthy individuals and HIV-1 infected patients,
treated and naïve to treatment. With the purpose of pin-
pointing the possible impact of age and HIV-1 infection on
the phenotype of B cell subpopulations, we measured the
expression of inhibitory molecules (PD-1 and FcRL4) and
activation markers (CD25 and CD69) on B cell subpopula-
tions in healthy controls and HIV-1 infected subjects, and
related these findings to the ability of B cells to respond to
activation signals. A detailed statistical analysis is presented
to characterize the impact of age and length of treatment
on phenotypical changes occurring in B cell subpopula-
tions during HIV-1 infection.
Results
Effect of HIV-1 infection, ART and aging on B cell
subpopulations
We initiated the study by assessing the frequency and
changes induced by HIV-1 infection in Naive CD19+
CD10−CD21+CD27−, Activated Memory (AM) CD19+
CD10−CD21−CD27+, Resting Memory (RM) CD19+
CD10−CD21+CD27+ and Tissue Like Memory (TLM)
CD19+CD10−CD21−CD27− B cell subsets in the three
groups studied (controls, HIV-1 non-treated and HIV-1
treated) independently of age (Additional file 1: Figure
S1 and Additional file 2: Figure S2). As previously re-
ported [15], HIV-1 infection leads to a significant reduc-
tion of the RM B cell subset that is not corrected by
treatment (P < 0.001) when comparing treated and non-
treated individuals to controls. Furthermore, HIV-1 in-
fection results in a significant increase in the frequency
of AM B cells (P < 0.05 and P < 0.001) when comparing
treated and non-treated individuals to controls; this in-
crease was corrected to some extent, but not normal-
ized, by treatment (P < 0.05) (Additional file 2: Figure
S2). The significantly increased percentages of TLM B
cells (P < 0.001) identified when comparing non-treated
and treated individuals to controls were partially cor-
rected by ART administration (P < 0.01) (Additional file
2: Figure S2). We did not identify a significant difference
in the frequencies of naive B cells between the groups
studied.
In order to investigate the influence of age, and age in
combination with HIV-1 infection, on the frequency of
peripheral blood B cell subsets, the study subjects were
divided into three age categories: 30 years or less (defined
as young), between 31 to 50 years (defined as middle) and
51 years and above (defined as aged). Table 1 shows the
descriptive statistics of subject age in each age group and
population.
The comparisons of the average percentages for B cell
subsets showed significant differences between age
groups, mostly in the B cell subsets of treated individuals











Control < =30 27 21-30 (25.85) ND ND 1.00 (0.41-1.84) NA NA
Non-treated < =30 14 23-30 (25.36) 628 (394–1096) 1188 (630–2096) 0.61 (0.23-1.19) 102070 (20-1×106) NA
Treated < =30 18 21-30 (25.61) 580 (308–1169) 862 (307–1567) 0.68 (0.32-1.33) 156 (0–893) 9.2 (1–48)
Control 31 = <<=50 38 31-50 (39.97) ND ND 1.93 (0.23-5.47) NA NA
Non-treated 31 = <<=50 10 31-47 (38.30) 559 (278–1357) 985 (421–1762) 0.7 (0.19-2.03) 33132 (233–1.3×105) NA
Treated 31 = <<=50 24 31-50 (41.88) 589 (222–2010) 884 (322–2175) 0.79 (0.15-1.96) 6 (0–36) 74.1 (2–160)
Control > =51 36 51-87 (58.83) ND ND 2.12 (0.88-5.17) NA NA
Non-treated > =51 11 51-85 (64.36) 604 (336–1235) 1334 (613–3185) 0.51 (0.16-0.92) 39886 (0–1.2×105) NA
Treated > =51 28 51-76 (57.46) 599 (247–1412) 895 (473–1452) 0.74 (0.20-2.99) 25.2 (0–343) 64.1 (2–163)
ND = Not Done.
NA = Not applicable.
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significantly increased percentages of naïve B cells (P <
0.01) and significantly decreased levels of AM (P < 0.01
and P < 0.05, respectively) B cells when compared to the
young treated group (Figure 1). A significant increase of
TLM B cells was seen in the non-treated group when
comparing young and aged (p < 0.05). A decline of naive
B cells according to age was noticed in non-treated pa-
tients (66.04%, 64.41 and 55.86 respectively) although
this difference did not reach significant levels.
Furthermore, we assessed the impact of HIV-1 infec-
tion and ART on B cell subpopulations for the different
age groups (Figure 2). The level of naive B cells signifi-
cantly increased after ART treatment in the aged group
(P < 0.05) when compared to the non-treated group
(Figure 2). A decrease in frequency of naive B cells in
the young group was detected when comparing controls
to treated individuals (P < 0.05). As previously observed
[15], the percentages of RM B cells in the non-treated
and treated groups are significantly decreased as com-
pared to controls in the middle (P < 0.01 and P < 0.05,
respectively) and aged group (P < 0.05 and P < 0.01, re-
spectively); the same clear trend was observed in the
young group although the values did not reach statistical
significance (Figure 2).
In addition, HIV-1 infection significantly increases the
frequency of AM in both middle and aged groups (P <
0.01) and of TLM B cells in young, middle and aged
groups (P < 0.01, P < 0.001 and P < 0.001, respectively)
when comparing non-treated to the controls; the in-
creased cell frequencies were corrected after ART ad-
ministration in the aged and middle groups to levels
comparable to the control group (Figure 2). Of interest
is that an increased frequency of AM (P < 0.001) and
TLM (P < 0.001) B cells was found in the treated young
group when comparing to controls; this finding is likely
due to the relatively short period of ART in these young
individuals.Regression analysis of the dependence of B cell sub-
population frequencies on age and treatment duration
(Table 2) lends support for the positive effect of ART on
correcting the levels of AM and TLM B cells in HIV-1
infected patients and further reinforces the conclusion
that treatment and/or age have no effect on restoring
the frequency of RM B cells in treated HIV-1 infected
patients.
To assess the effect of treatment duration as well as
age on frequencies of AM and TLM B cells, we subdi-
vided our treated patients into groups with different age
and ART duration, as illustrated in Figure 3. We com-
pared the mean percentages of AM and TLM B cells of
these treated, HIV-1 infected groups to the same age
groups of the controls. We found that young HIV-1 in-
fected patients with short ART duration have higher
mean percentages of AM and TLM B cells significantly
different from each of the control age groups (Figure 3).
In addition the AM levels in the young HIV-1 infected
patients with short ART duration are significantly differ-
ent from the levels found in the treated patients in-
cluded in the middle and aged group. These analyses
confirm that the short treatment period in the young
treated patients is associated with the increased frequen-
cies of AM and TLM B cells; prolonged treatment appears
to be effective in reducing the levels of AM and TLM B
cells even in the young group of patients (Figure 3).
Finally, we compared each HIV-1 study population as
a whole to the different age groups of the controls, in
order to find whether the treated or non-treated group
is more similar to a specific age group among the con-
trols. We did not detect any significant difference be-
tween the groups in regard to the frequency of naive B
cells (Figure 4). The non-treated patients have signifi-
cantly higher percentages of AM (P < 0.01, P < 0.001 and
P < 0.05, respectively) and TLM (P < 0.001) than all the
age groups of the controls. However, the treatment de-
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Figure 1 Percentages of B cell subsets in relation to age groups. The average percentages of B cell subsets in patients belonging to the age
groups < =30, 31–50 and > =51 years of age in healthy controls, non-treated and treated HIV-1 infected patients are shown. The specimens included in
the figure were obtained from the subjects presented in Table 1. The results are illustrated for the different subsets: Naive, resting memory (RM), activated
memory (AM) and tissue-like memory (TLM) B cells. * = P < 0.05, ** = P < 0.01.
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in the young and middle control groups. In contrast, the
percentages of RM B cells in non-treated and treated
group are lower than RM B cells of all control groups
(Figure 4).
All in all, the above results show that while treatment
corrects several of the effects of HIV-1 infection, neither
treatment nor aging, nor their combination, affect the
decrease in the percentage of RM B cells caused by
HIV-1 infection.
Expression of the activation markers CD25 and CD69 on
B cell subpopulations
In order to understand whether phenotypic changes take
place in B cell subsets with age in combination with HIV-1
infection, a panel of phenotypic markers including B cellinhibitory receptors PD1 and FcRL4 and activation mole-
cules CD25 and CD69 was used. For the purpose we char-
acterized specimens from young and aged healthy subjects
(n = 30) and HIV-1 infected individuals (n = 63; 22 naïve
and 41 on ART) (age ranges and characteristics indicated
in Table 3).
To evaluate the changes that HIV-1 infection induces
in B cell phenotype, we first compared young individuals
in the three study groups to each other in regard to the
expression of inhibitory receptors on B cell subsets
(Figure 5A). The expression of PD1 was not different
among groups on any B cell subset studied. The expression
of FcRL4 was significantly higher on TLM B cells in the
non-treated group compared to the controls (P < 0.05).
The comparison (Figure 5A) of the inhibitory receptor
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Figure 2 Percentages of B cell subsets in relation to HIV-1 infection and treatment. The average percentages of B cell subsets in controls,
non-treated and treated HIV-1 patients are shown for each age group (<=30, 31–50 and > =51 years of age). The specimens included in the figure
were obtained from the subjects presented in Table 1. The results are illustrated for the different subsets: naive, resting memory (RM), activated
memory (AM) and tissue-like memory (TLM) B cells. * = P < 0.05, ** = P < 0.01, *** = P < 0.001.
Amu et al. Retrovirology 2014, 11:76 Page 5 of 13
http://www.retrovirology.com/content/11/1/76groups of aged individuals (control, non-treated, treated)
revealed no difference in any B cell subset studied.
Interestingly, in young individuals, the expression of
CD25 activation marker was significantly reduced on the
RM (P < 0.001) and AM (P < 0.01) subsets of B cells fromTable 2 Regression analysis of the dependence of B cell subp
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Each row represents the regression result for one B cell subpopulation. For each po
the correlation coefficient between the specific B cell subpopulation and the chosenon-treated patients when compared to the controls
(Figure 5B). Similarly, the expression of CD25 in the
treated group was significantly lower on all B cell sub-
sets (ranging from P < 0.001 to P < 0.01) when compared







pulation, the variables that were found predictive are marked with a “+”. R2 is
n predictive variable(s). P values in bold indicate significant difference.
Figure 3 Effect of treatment duration and age on AM and TLM subset frequencies. To assess the effect of treatment and age on AM and TLM
subset distribution we arbitrarily divided 69 of the 70 treated patients presented in Table 1 into 5 groups: 13 young with short treatment periods (YS)
[age 21–30 and mean (range) length of ART treatment 1.8 (1–6) months], 5 young with long treatment periods (YL) [age 21–30 and 28.4 (18–48) months
of ART], 23 in the middle age group with long treatment periods (ML) [age 31–50 and 66.8 (16–160) months of ART], 8 aged with short treatment
periods (AS) [age 51–64 and 5.6 (2–12) months of ART], and 20 aged with long treatment periods (AL) [age 51–64 and 87 (15–163) months of ART]. We
had only one patient in the middle group with a short treatment period and accordingly we excluded this patient from the analysis. The treated patients
were compared to the control group divided into young (YC; N = 27), middle (MC; n = 38) and aged (AC; n = 36) according to Table 1. * = P < 0.05,
** = P < 0.01, *** = P < 0.001.
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fected individuals (Figure 5B).
As noticed for the young group of HIV-1 infected
patients, the expression of CD25 in the aged group was
significantly lower on RM, AM and TLM B cells from the
non-treated when compared to the controls (P < 0.001;
P < 0.001 and P < 0.05 respectively). Treatment did not re-
store any of these differences (Figure 5B). We also identi-









Figure 4 B cell subsets from HIV-1 infected patients in relation to age
non-treated and treated individuals of all ages were compared to the three
were obtained from the subjects presented in Table 1. The average percen
(RM), activated memory (AM) and tissue-like memory (TLM) B cells. * = P < 0Naive, RM, AM and TLM B cells of the aged non-treated
patients (P < 0.001, P < 0.01, P < 0.001 and P < 0.001
respectively) when compared to the controls (Figure 5B).
ART did not correct for the low expression of CD69 in B
cells from HIV-1 infected individuals which remained low
in all subpopulations and significantly differed for Naive
(P < 0.01) and TLM B cells (P < 0.01).
When the levels of expression of CD25 and CD69





























groups from healthy controls. B cell subsets from HIV-1 infected,
age groups of healthy controls. The specimens included in the figure
tages are illustrated for the different subsets of naive, resting memory
.05, ** = P < 0.01, *** = P < 0.001.
Table 3 Characteristics of young and aged individuals used for phenotypic characterization
Controls Treated Non-treated
Parameters Young Aged Young Aged Young Aged
Number of patients 15 15 23 18 11 11
Age (mean age) 21-26 (23.9) 57-87 (62.7) 21-32 (26.9) 51-76 (58.2) 23-25 (24.3) 51-85 (63.9)
CD4 cells/μl (range) ND ND 645 (308–2010) 544 (314–1052) 637 (394–1096) 604 (336–1235)
Virus load copies/ml (range) NA NA 128 (0–893) 37.8 (0–343) 1.2×105 (20-1×106) 4.3×104 (65–1.2×105)
Length of ART Months (range) NA NA 14.4 (1–50) 20.1 (1–74) NA NA
ND = Not determined.
NA = Not applicable.
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observation were made: the level of CD25 on B cell
subpopulations are equally low in young and old HIV-1
infected individuals and not corrected by ART treat-
ment. Interestingly, the different CD69 expression de-
tected in aged controls and HIV-1 infected patients
appears to be the result of an increased expression of
this molecule in aged healthy controls and does not
reflect the virus effect on B cells from aged HIV-1 in-
fected patients.
The effect of age and length of therapy on B cell
phenotypical changes
We next assessed whether differences in B cell phenotype
of HIV-1 infected subjects on ART (including the low
expression of CD69 and CD25) depend on age and length
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Figure 5 Exhaustion and activation markers on B cell subsets. Panel A
FcRL4) and panel B markers of activation (CD25 and CD69) on B cell subse
and aged individuals. The specimens included in the figure were obtained
illustrated for the different subsets of naive, resting memory (RM), activated
** = P < 0.01, *** = P < 0.001.analysis including age, treatment duration and the inter-
action between them as continuous independent parame-
ters, and assessed whether these parameters affect the
phenotype of B cell subpopulations – which are the
continuous dependent variables. A total of 41 HIV-1
infected subjects between 21–76 years of age, receiving
ART were included in the analysis, 23 young and 18
aged (see Table 3 for virological and immunological
details); the length of ART treatment, ranging between
1–74 months, was comparable in the two groups of
young and aged treated patients.
Table 4 shows the results of the stepwise regression
analysis. When analysing the phenotype patterns (in-
cluding expression of PD1, FcRL4, CD25 and CD69) in
all B cell subpopulations, we found only weak correla-
tions between the specific subpopulations and the




shows the expression of surface markers of exhaustion (PD1 and
ts which was compared in controls, non-treated and treated young
from the subjects presented in Table 3. The average expression is
memory (AM) and tissue-like memory (TLM) B cells. * = P < 0.05,
Table 4 Regression analysis of B cell phenotypical
changes in relation to age and treatment duration
B cell
phenotype
Variables included in the model R2 P value





AM_FcRL4 + 0.109 0.035
RM_FcRL4 0.020 0.372
NAÏVE_FcRL4 0.015 0.452
TLM_FcRL4 + 0.135 0.018
AM_CD25 + 0.127 0.022







Each row represents the regression result for one B cell subpopulation. For
each population, the variables that were found predictive are marked with a
“+”. R2 is the correlation coefficient between the specific B cell subpopulation
and the chosen predictive variable(s). P values in bold indicate significant
difference.
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seen in the AM and RM B cells expressing CD25, and,
AM and TLM B cells expressing FcRL4. However, even
for these significant values, the highest correlation coef-
ficient (R2) was 0.172, indicating that only 17.2% of the
total variation in the frequency of RM CD25 expressing
B cells is explained by treatment duration. Our regres-
sion analysis (Table 4) shows that age, treatment dur-
ation and the interaction between them do not affect
differences in the expression of exhaustion and activa-
tion markers on B cells from HIV-1 infected subjects
undergoing treatment.
Expression of CD25 and CD69 on B cells correlates with
the capacity of B cells to respond to in vitro activation
stimuli by intracellular IL-6 expression
To determine if the low expression of surface CD25 and
CD69 on B cells could be linked to any functional impair-
ment in these cells, we stimulated cells from both controls
and HIV-1 infected individuals and assessed the intracel-
lular expression of the IL-6 cytokine (Figure 6). IL-6, a
multifunctional cytokine, important for many aspects of B
cell differentiation and antibody production is produced
by multiple cell types including activated B cells. A signifi-
cant positive correlation was found between the surface
CD25 expression and percentages of total B cells (P < 0.01and r = 0.379) and CD27+ memory B cells (P < 0.001 and
r = 0.429) expressing IL-6 following in vitro stimulation
(Figure 6). A similar positive correlation was found
between IL-6 expression and surface CD69 expression on
all B cells (P < 0.01 and r = 0.360), naive B cells (P < 0.001
and r = 0.450) and memory B cells (P < 0.05 and r = 0.269)
(Figure 6). These results indicate that low surface expres-
sion of activation markers CD25 and CD69 on the B cell
is linked to a weaker response of B cells to exogenous
activating stimuli.
Discussion
HIV-1 infection, in view of its chronicity, has been postu-
lated to induce detectable changes of premature aging in
the immune system. The changes occurring in B cells dur-
ing aging of HIV-1 infected individuals have yet not been
fully characterized. In the current study, to investigate the
impact of HIV-1 infection on B cell aging, we have com-
pared the frequency, surface markers and intracellular IL-6
expression in response to activation of multiple B cell sub-
sets in the blood of healthy and HIV-1 infected individuals.
It is still controversial whether age affects the total
number of B cells, as opposite results have been pre-
sented in this context [25,26]. When subdivided into
subsets, a decline of naïve B cells has been shown during
aging in healthy individuals, whereas memory B cells
(CD27+) have been found slightly decreased in some re-
ports and increased in other studies [27-29]. Memory B
cells against specific pathogens, however, increase during
aging as demonstrated for cytomegalovirus (CMV) [30].
In our control group, the levels of naïve B cells and all
memory B cell populations (RM, AM and TLM B cells)
remained constant at different ages.
Interestingly, we found that HIV-1 infection impacts
similarly on the distribution of B cell subpopulations in
all age groups, but the effects of treatment are not the
same. In our study, depletion of RM B cells taking place
in all age groups during HIV-1 infection was not cor-
rected by ART. HIV-1 infected patients have increased
percentages of AM and TLM B cells in the middle and
aged groups, but the treatment, when provided for more
than 12 months, significantly reduces these percentages to
levels that are comparable to those of controls (Figure 3);
longer treatment periods in the young HIV-1 infected
group also appears to normalize the levels of AM and
TLM B cells (Figure 3). Thus, the restored frequencies of
AM and TLM B cells in the middle and aged group are
likely the result of longer treatment periods, allowing time
for ART to correct for alteration to the B cell phenotype,
rather than age itself.
Furthermore, our data show important differences in
the surface expression of B cell markers between healthy
individuals and subjects with HIV-1 infection. Both aged
and young controls had the highest expression of CD25













Figure 6 Association of surface CD25 and CD69 expression on B cells with intracellular IL-6 expression. The percentages of total, naïve
and memory (CD27+) B cells expressing CD25 and CD69 were correlated with cells expressing intracellular IL-6 following in vitro stimulation with CpG
and CD40L. Specimens from 60 individuals are included in the analysis: 21 HIV-1 infected individuals naïve to treatment, 19 HIV-1 infected patients on
ART and 20 age matched controls. The P values were derived using the Spearman correlation test.
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dividuals (Additional file 3: Figure S3). CD25 (alpha chain
of the IL-2 receptor), although present on some naive B
cells, is highly expressed on the surface of CD27+ memory
B cells [31]. Low CD25 expression has been previously
detected on memory B cells of HIV-1 patients [32]. In the
same study the levels of plasma IL-2 were directly corre-
lated with the low frequency and survival of memory B
cells in a STAT5 and Foxo3a dependent manner [32].
Serum levels of IL-2 are decreased during HIV-1 infection
[33] and decreased production of IL-2 by T-cells, the main
IL-2 producing cells, has been shown in healthy individ-
uals with advanced age [34]. Co-cultures of CD25 express-
ing B cells with CD4+ T-cells in the presence of low IL-2
concentrations resulted in T-cell anergy, while high IL-2
concentration induced T-cell proliferation [35]. It has also
been shown that CD25 expressing B cells induce FoxP3+
regulatory T-cells in co-culture [36]. The low expression
of CD25 on memory B cells during HIV-1 infection may
thus lead to two important consequences: 1) impaired
proliferation and survival of B cells, and 2) impaired inter-
actions with T-cells and T-cell differentiation.
Chronic activation during HIV-1 infection results in
the accumulation of exhausted B cell subsets express-
ing multiple inhibitory receptors such as FcRL4 and
PD1, which contribute to inefficient immune responses
against the virus. Expression of PD1 on B cells has
been linked with memory B cell depletion andimpaired humoral responses in SIV-infected macaques
[37]. Additionally, PD1 has been shown to be present
on multiple B cell subsets in healthy individuals and
has an inhibitory effect on B cell activation [38]. FcRL4
or Fc receptor–like proteins are trans-membrane pro-
teins previously described to be expressed on a unique
population of memory B cells, termed TLM, in human
lymphoid tissues near epithelial surfaces [39]. We
could not detect differences in PD1 expression for the
different subsets; the expression of FcRL4 was however
increased in TLM B cells of young non-treated pa-
tients and this change was corrected by ART. Previ-
ously it has been shown that silencing of the FcRL4
receptor with siRNA in TLM B cells from HIV-1
patients resulted in increased secretion levels of HIV-1
specific antibody, in addition to production of B cell
associated cytokines and chemokines [40].
The expression of FcRL4 on human B cell lines disrupts
immune synapse formation and blocks antigen induced
BCR signaling, in addition to CD69 expression [41]. CD69
is an early activation marker mainly expressed by activated
T, B and natural killer cells. CD69 acts down-stream the
IFN alpha/beta signaling and affects lymphocyte migration
from lymph nodes through S1P1 inhibition [42]. When
comparing young and aged control individuals, there is a
higher expression of CD69 in aged control individuals on
all the B cell subsets studied (for naïve and TLM B cells
P < 0.05). The same elevation in CD69 expression could
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viduals (Figure 5 and Additional file 3: Figure S3).
Whether elevation of CD69 expression in the aged con-
trols, but not in the patients, play a relevant biological role
for B cell immunology needs to be verified in additional
studies.
We could further show that B cells expressing low levels
of CD25 and CD69, including naive and memory B cells
and independently of the studied groups, have a poor
response to exogenous stimuli as detected by the low
expression of intracellular IL-6. IL-6 a pro-inflammatory,
multifunctional cytokine plays a key role in B cells activa-
tion, terminal differentiation and antibody production
[43]. High serum levels of IL-6 during HIV-1 infection
have been previously associated with increased levels of
activated memory B cells [44]. Further studies using larger
number of HIV-1 infected patients need to be conducted
to clarify the link between B cell phenotype and B cell
activation.
It can then be asked whether aging results in profound
changes in the phenotype and function of B cell subsets
during HIV-1 infection. The decline of RM B cells,
although due to virus infection rather than to the aging
process, affects dramatically all age groups during HIV-1
infection and is not reverted by ART treatment. In
addition, B cell subpopulations of HIV-1 infected patients
of all age have reduced levels of the CD25 marker (alpha
chain of the IL-2 receptor) which is not corrected by ART.
Conclusions
The present study shows that RM B cells in young and
aged HIV-1 infected patients are reduced in frequency
and exhibit a reduced expression level of the activation
marker CD25. On the other hand, elevated frequencies
of AM and TLM B cells in young and aged patients, are
correct by prolonged ART treatment. Age per se does
not appear to worsen impairment induced in the B cell
compartment by HIV-1 infection.
These pathological findings in HIV-1 infected patients
suggest that, in spite of prolonged treatment, some as-
pects of B cell impairments persist in both young and
aged HIV-1 infected patients. In view of these findings,
following prolonged ART, re-vaccination against com-




Subjects included in the study were HIV-1 infected in-
dividuals naive to treatment [n = 35; defined as non-
treated; mean age (age range) 41.3 (23–85) years], on
ART [n = 70; defined as treated; 43.9 (21–76) years],
and HIV-1 negative healthy individuals [n = 101;
defined as controls; 42.9 (21–87) years]. The meanCD4+ T-cell count/μl in the non-treated group was
601 (range 278–1357) and in the treated group 591
(222–2010). The viral load ranged between 20-1×106
copies/μl in the blood of non-treated patients and 0–893
copies/μl in treated patients. The individuals included in
the study were divided into 3 age group categories accord-
ing to the overall population mean age: Low: Age <Mean -
1 SD, Medial: (Mean-1 SD <Age <Mean + 1 SD) and High:
Age >Mean + 1 SD.
In order to elucidate the impact of age and HIV-1 in-
fection on phenotypic markers of B cell subpopulations,
a panel of specimens from individuals belonging to the
three groups defined above, a total of 30 healthy subjects
and 63 HIV-1 infected individuals (22 naïve to treatment
and 41 treated) was further characterized for surface
phenotype. We first identified the youngest and the old-
est individuals in our 2 groups of HIV-1 infected
subjects and then matched the healthy controls to the
patients. The age, CD4+ T-cell counts, viral load and
ART duration for these individuals are presented in
Table 3. The young and aged groups of HIV-1 treated
patients were matched for length of treatment (up to
74 months).
For the regression analysis presented in Table 4 a total
of 41 HIV-1 infected subjects between 21–76 years of
age, receiving ART were included in the analysis, 23
young and 18 aged (see Table 3 for virological and
immunological details). The length of ART treatment
was comparable in the two groups of young and aged
treated patients.
Cell isolation and phenotyping
Peripheral blood mononuclear cells (PBMCs) were iso-
lated using Ficoll gradient centrifugation (Lymphoprep,
Axis-Shield Poc AS, Oslo, Norway). Cells were washed,
counted using Countess automated cell counter (Invitro-
gen, NY, USA) and used for flow cytometry analyses. The
study was approved by the ethical committee at Karo-
linska Institutet and informed consent was obtained from
all the individuals included in the study.
For flow cytometric analyses, isolated PBMCs were
plated at 1-2×106 cells per sample and stained using
fluorochrome-conjugated antibodies in different combi-
nations: V450 CD3 (clone UCHT1), PE CD4 (clone
RPA-T4), V500 CD8 (RPA-T8), PerCp-Cy5.5 anti-CD19
(clone HIB19), FITC anti-CD10 (W8E7), V450 anti-
CD27 (MT271) and anti-CD21 (B-ly4), APC anti-CD21
(B-ly4), PE anti-CD27 (M-T271), anti-PD1 (MIH4), anti-
CD25 (M-A251) and anti-CD69 (FN50) all from (BD
Biosciences, CA, USA). APC anti-FcRL4 (413D12) was
from BioLegend. LIVE/DEAD Fixable Near-IR kit (Invi-
trogen) was used to exclude the dead cells from analyses.
Cells were washed three times before being fixed in
1% formaldehyde. All antibodies were used in the
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Matched isotype controls or FMO were used to set up
the gates. Fluorescence intensities were measured with
Cyan ADP (Beckman Coulter) and data were analysed
using FlowJo, version 9.4.11 (Tree star, OR, USA). In
order to derive the CD4:CD8 ratio for T cells from the
healthy controls, the frozen PBMCs were used.
Identification of B cell subsets
Peripheral whole B cell population was gated out as CD19+
cells after exclusion of dead cells. Whole B cells were
further subdivided into various B cell subsets: Naive
CD19+CD10−CD21+CD27−, Activated Memory (AM)
CD19+CD10−CD21−CD27+, Resting Memory (RM)
CD19+CD10−CD21+CD27+ and Tissue Like Memory
(TLM) CD19+CD10−CD21−CD27− B cells; the gating
strategy is illustrated in Additional file 1: Figure S1. Whole
memory B cells were identified as CD19+CD10−CD27+.
Intracellular cytokine detection
PBMCs were cultured at a concentration of 2×106 cells/
ml in RPMI-1640 containing L-glutamine, 10% FCS and
antibiotics in medium only or stimulated with 10 μg/ml
CpG-B (InvivoGen, California, USA) and 1 μg/ml CD40L
(InvivoGen) for 48 h. For the last 5 hours of the culture,
an additional stimulation with 50 ng/ml PMA and 1 μg/
ml Inomycin (Sigma-Aldrich, MO, USA) in the presence
of Golgistop used at 1:1000 dilution (BD) was per-
formed. Cells were first stained for cell surface markers
PerCp anti-CD19, FITC anti-CD10 and V450 anti-CD27
in addition to LIVE/DEAD staining. In next step cells
were fixed and permeabilized using BD Cytofix/Cyto-
perm kit and stained with PE anti-IL-6 (MQ2-6A3) and
matching isotype control, both from (BD). Cells were
washed and fixed in 1% formaldehyde before the ana-
lysis were conducted using a Cyan flow cytometer. Col-
lected data were analysed using FlowJo, version 9.4.11
(Tree star).
Statistical analysis
One-way ANOVA with Newman-Keuls post-test was used
when multiple groups were compared. The correlation
data were analysed using the Spearman correlation test.
In order to dissect the effects of age versus length of
therapy on phenotypical alterations (expression of PD1,
CD25, CD69 and FcRL4) taking place on B cell subpop-
ulations, we performed regression analysis. We used a
stepwise regression method, which uses an automatic
procedure in order to decide which of the independent
variables are the predictive ones. Age, treatment
duration and the interaction between them are the pos-
sible predictive variables, and they were included in the
regression analysis according to the p value of the F-
tests. We used the backward elimination method forchoosing the predictive variables. This method starts
with all possible predictive variables as candidates, de-
letes each variable, one by one, and tests whether the
deletion improved the correlation between the B cell
phenotype and the predictive variables that were not
deleted. This process is repeated until no further im-
provement in the correlation is achieved.
Data were analysed using SPSS version 20 and graphed
using Prism version 5.0a (GraphPad Software, La Jolla,
California, USA).
Additional files
Additional file 1: Figure S1. Gating strategy for identification of B cell
subsets.
Additional file 2: Figure S2. Percentages of B cell subpopulations in
control individuals, non-treated and treated HIV-1 patients. The specimens
included in the figure were obtained from 101 healthy controls, 35 HIV-1
infected subjects naïve to treatment and 70 HIV-1 infected subjects
receiving ART (Table 1). * = P < 0.05, ** = P < 0.01, *** = P < 0.001.
Additional file 3: Figure S3. Changes in expression of phenotype
markers CD25 and CD69 in relation to age and infection. The
expression of phenotype markers was compared in all subsets of
B-cells between young controls and aged controls, HIV-1 infected
individuals naive to treatment and on treatment. * = P < 0.05, ** = P < 0.01,
*** = P < 0.001.
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